DETERMINATION OF THE IMPACT OF BISOPROLOL AND СARVEDILOL ON REGULATORY-ADAPTIVE STATUS OF PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT VENTRICULAR FRACTION

Objective. To determine the effect of bisoprolol or carvedilol therapy on the regulatory-adaptive status (RAS) of patients with chronic heart failure (CHF) and preserved ejection fraction (pEF) of the left ventricle (LV) the background of hypertensive disease (HD).

Material and methods. The study involved 68 patients with CHF and pEF of the LV, who were randomized into two groups for treatment with bisoprolol (7,3±2,4 mg/day, n=34) and carvedilol (28,4±12,3 mg/day, n=34). As part of the combination therapy, quinapril was prescribed (13,5±2,5 mg/ day, n=34 and 12,6±2,9 mg/day, n=34), and if indicated – atorvastatin (16,3±5,0 mg/day, n=11 and 15,5±5,2 mg/day, n=11) and acetylsalicylic acid in the intestinal soluble shell (93,8±17,7 mg/day, n=8 and 94,4±15,8 mg/day, n=8), respectively. Initially and after 6 months of therapy were carried out: quantitative assessment of RAS (by means of a sample of cardiac-respiratory synchronism), treadmill test, six-minute walking test, subjective assessment of quality of life, determination of the level of N-terminal fragment of brain natriuretic peptide, echocardioscopy, daily monitoring of blood pressure.

Results. Both regimens of combined drug therapy had comparable cardioprotective, hypotensive and neuromodulating effects, equally increased exercise tolerance. In comparison with bisoprolol, carvedilol differed positive impact on RAS, improved quality of life more.

Conclusion. In patients with CHF and pEF LV in combination therapy, the use of carvedilol, in comparison with bisoprolol, may be preferable due to the positive effect on the RAS.

1. Mareev V.Yu., Fomin I.V., Ageev F.T., et al. Clinical guidelines. Chronic heart failure (CHF). Russian Heart Failure Journal. 2017; 18 (1): 3-40 (in Russ.)

2. Münzel T., Gori T., Keaney J.F. at al. Response to Letters Regarding Article, Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2019; 132 (16): 205-206.

3. Kurkina M.V., Avtandilov A.G., Krutovcev I.A. Role of factors affecting the formation of chronic heart failure with preserved ejection fraction. Rational Pharmacotherapy in Cardiology. 2017; 13 (5): 615-621 (in Russ.)

4. Hunt S.A., Abraham W.T., Chin M.H. et al. Focused update incorporated info the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of American college of cardiology foundation/American heart association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. Journal of the American college of cardiology. 2009; 53 (15): 1-90.

5. Pokrovskii V.M., Potiagaylo E.G., Abushkevich V.G. et al. Cardio-respiratory synchronism: detection in humans, dependence on the properties of the nervous system and functional states of the body. Advances in physiological sciences. 2003; 34 (3): 68-77 (in Russ.)

6. Pokrovskii V.M., Ponomarev V.V., Artyushkov V.V. et al. System for determining cardio-respiratory synchronism in humans. Russia, patent № 86860,2009.

7. Puchniak D.V., Mingalev A.N., Patakhov P.P. et al. Parameters of a sample of cardio-respiratory synchronism in the evaluation of stress tolerance of human basic research. 2017; 9 (2): 287-289 (in Russ.)

8. Pokrovskii V.M., Polischuk L.V. Cardiorespiratory synchronism in estimation of regulatory and adaptive organism status. Journal of Integrative Neuroscience. 2016; 15 (1): 19-35. doi: 10.1142/S0219635216500060

9. Tregubov V.G., Kanorskii S.G., Pokrovskii V.M. Quantitative assessment of the regulatory-adaptive status in determining the prognosis for systolic chronic heart failure. Clinical Medicine. 2015; 93 (11): 22-28 (in Russ.)

10. Tregubov V.G., Shubitidze I.Z., Kanorskii S.G., Pokrovskii V.M. regulatory-adaptive status in comparison of bisoprolol and sotalol efficacy in ventricular rhythm disorders. Russian Journal of Cardiology. 2018; (1): 51-56 (in Russ.) https://doi.org/10.15829/1560-4071-2018-1-51-56

11. Tregubov V.G., Eremina M.A., Kanorskii S.G., Pokrovskii V.M. Comparison of treatment efficacy in paroxysmal atrial fibrillation. Cardiovascular Therapy and Prevention. 2017; 16(2): 46-51 (in Russ.) https://doi.org/10.15829/1728-8800-2017-2-46-51

12. Nazhalkina N.M., Tregubov V.G., Pokrovskii V.M. Regulatory adaptive status in determining the effectiveness of bisoprololum and sotalolum in patients with hypertensive disease and paroxysmal supraventricular tachycardia. Kardiologiia. 2017; 57(1S): 345-354 (in Russ.). https://doi.org/10.18087/cardio.2396

13. Martsevich S.Y., Zakharova N.A., Kutishenko N.P., et al. Сlinical practice of betablockers usage in patients with cardiovascular and chronic respiratory diseases. Data of outpatient registries profile and recvasa. Rational Pharmacotherapy in Cardiology. 2017; 13 (4): 469-475 (in Russ.)

14. Frоhlich H., Torres L., Tаger T. et al. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol. 2017; 106 (9): 711-721. doi: 10.1007/s00392-017-1115-0.